Addex Therapeutics (APE1) AI Stock Analysis

Addex Therapeutics

(Frankfurt:APE1)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Advancing CNS pipelineThe lead GABAB PAM candidate has cleared IND-enabling work and is ready to enter clinical development, while several other CNS programs are advancing. This breadth creates multiple opportunities for clinical validation, partnering, and future milestone value rather than relying on one asset.

Negative Factors

Very weak and declining revenueExtremely low and declining revenue shows that Addex has not yet established meaningful commercial scale and remains dependent on partnering-related economics. Volatile or limited revenue reduces internal funding capacity and makes future operating results heavily dependent on development milestones.

Addex Therapeutics (APE1) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 3.81M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.5
Beta (1Y): 1.02
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 3
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Addex Therapeutics Business Overview & Revenue Model

Company Description

Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core...

Addex Therapeutics Earnings Call Summary

Earnings Call Date:Sep 27, 2026(Q2-2026)|% Change Since:-14.19%|Next Earnings Date:May 19, 2020

Earnings Call SentimentPositive

The call was predominantly positive, highlighting a $2.8 million financing, cash runway into Q4 2027, regained rights to the GABAB PAM platform, multiple advancing preclinical and clinical programs, and encouraging chronic cough and substance use disorder data. Offsetting factors included the CHF 0.8 million half-year cash balance, CHF 1.2 million of operating cash use, a stable CHF 3.4 million net loss, increased share of Neurosterix losses, and the need to secure financing before advancing certain programs.

Positive Updates

Balance Sheet Strengthened and Runway Extended

Addex raised $2.8 million through its ATM facility in Q3, providing a cash runway into Q4 2027.

Negative Updates

Limited Cash Balance at Half-Year End

Addex ended H1 2026 with CHF 0.8 million in cash, compared with CHF 1.6 million as of December 31, 2026, a decrease of CHF 0.8 million primarily due to operating costs, partially offset by the sale of treasury ADSs.

Company Guidance

Addex said the GABAB PAM substance use disorder candidate is ready for IND filing and phase I clinical trials, with the next milestone being the filing of an IND, while IND enabling studies for the chronic cough program are “planned and ready to start subject to securing financing”; it expects phase I data from Neurosterix’s NTX-253 program in Q4 this year, NTX-529 IND-enabling studies should start shortly, NTX-819 is expected to complete IND-enabling studies in the coming months, and it continues to prepare dipraglurant for phase II in post-stroke recovery. The company said it raised $2.8 million in Q3 through its ATM facility, providing cash runway into Q4 2027, and that patents filed in 2024, if granted, are expected to expire in 2044.

Addex Therapeutics Risk Analysis

Addex Therapeutics disclosed 54 risk factors in its most recent earnings report. Addex Therapeutics reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk

1.We were an "emerging growth company" for the financial reporting published until December 31, 2025 and it is possible that investors have found or will continue to find shares or our ADSs less attractive.Q4, 2025

Addex Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:APE1 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KPRX	43Neutral	$6.90M	-0.62	-63.39%	―	―	19.38%
HCWB	42Neutral	$2.46M	-0.02	-142.16%	―	707.02%	70.52%
XBIO	42Neutral	$4.80M	-1.72	-40.62%	―	33.30%	40.59%
NCNA	33Underperform	$4.35M	-0.25	-41.95%	―	―	99.50%

* Healthcare Sector Average

Performance Comparison

DE:APE1 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:APE1	Addex Therapeutics Ltd (ADR)	2.66	-4.49	-62.80%
KPRX	Kiora Pharmaceuticals, Inc.	1.63	-0.74	-31.22%
XBIO	Xenetic Biosciences, Inc.	2.06	-0.79	-27.72%
NCNA	Nucana Plc	0.98	-2.65	-73.00%
CELZ	Creative Medical Technology Holdings, Inc.	0.62	-2.23	-78.14%
HCWB	Hcw Biologics, Inc.	1.12	-19.28	-94.51%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Addex Therapeutics AI Stock Analysis